The funding will help develop antibacterial peptides to treat drug-resistant infections in the lungs and other parts of the body.
CARB-X featured in The Philadelphia Inquirer.
Vedanta Biosciences Awarded $5.8 Million CARB-X Grant to Accelerate Development of VE707 for Multi-Drug Resistant Infections
Kevin Outterson quoted in BussinessWire.
Vedanta’s VE707 microbiome program is designed to accelerate the development of a new category of oral therapeutics to help a patient’s microbiota fight drug-resistant bacteria.
CARB-X Funds VenatoRx to Support Development of New Class of Oral Antibiotics to Treat Multi-Drug-Resistant Gonorrhoea
Kevin Outterson and CARB-X featured in Pharmaceutical Business Review.
The T2Resistance Panel is the only direct-from-blood diagnostic designed to detect genetic markers associated with antibiotic-resistant bloodstream infections
CARB-X Funds Techulon to Support the Development of Innovative Nano Therapeutics Capable of Killing Drug-Resistant Bacteria by Precisely Targeting Essential Genes
Techulon project is the 50th project funded by CARB-X since it was launched in 2016. (BOSTON, MA) – CARB-X is awarding Techulon Inc., located in the Virginia Tech Corporate Research Center in Blacksburg, VA, USA, up to $785,000 in non-dilutive funding to develop a new class of antimicrobial that would kill drug-resistant bacteria by targeting […]
BioVersys’ new medicine would be used as a stand-alone to treat uncomplicated skin and skin structure infections (SSSI) or in combination with antibiotics for more severe infections.
Kevin Outterson mentioned in NBC News.
BU Law professor Kevin Outterson and CARB-X featured in the Productivity Hub.